Limited Diagnostic Utility of Light Chain and IgA Subclass Staining in IgA-Type Monoclonal Gammopathy of Renal Significance

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 


 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
 
Limited Diagnostic Utility of Light Chain and IgA Subclass Staining in IgA-Type Monoclonal Gammopathy of Renal Significance

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Shun
Manabe
Shun Manabe shunmn5711@gmail.com Tokyo Women’s Medical University Department of Nephrology Tokyo Japan *
Anna Nakai nakai.anna@twmu.ac.jp Tokyo Women’s Medical University Department of Nephrology Tokyo Japan -
Momoko Seki seki.momoko@twmu.ac.jp Tokyo Women’s Medical University Department of Nephrology Tokyo Japan -
Yusuke Ushio ushio.yusuke@twmu.ac.jp Tokyo Women’s Medical University Department of Nephrology Tokyo Japan -
Rina Takahashi takahashi.rina_2@twmu.ac.jp Tokyo Women’s Medical University Department of Nephrology Tokyo Japan -
Shiho Makabe makabe.shiho@twmu.ac.jp Tokyo Women’s Medical University Department of Nephrology Tokyo Japan -
Shizuka Kobayashi kobayashi.shizuka@twmu.ac.jp Tokyo Women’s Medical University Department of Nephrology Tokyo Japan -
Naoko Ito ito.naoko@twmu.ac.jp Tokyo Women’s Medical University Department of Pathology Tokyo Japan -
Hiroshi Kataoka kataoka@twmu.ac.jp Tokyo Women’s Medical University Department of Nephrology Tokyo Japan -
Sekiko Taneda taneda.sekiko@twmu.ac.jp Tokyo Women’s Medical University Department of Pathology Tokyo Japan -
Junichi Hoshino hoshino.junichi@twmu.ac.jp Tokyo Women’s Medical University Department of Nephrology Tokyo Japan -
-
-
-
-

Monoclonal gammopathy of renal significance (MGRS) is defined by renal injury caused by the deposition of a monoclonal immunoglobulin. In IgG-type MGRS, diagnosis is often straightforward using immunofluorescence staining for IgG subclasses (IgG1–4) and κ/λ light chains. In contrast, IgA-type MGRS poses greater diagnostic challenges because most glomerular IgA deposits belong to the IgA1 subclass, and light chain predominance (κ or λ) is also frequently observed in polyclonal diseases such as IgA nephropathy (IgAN). The KM55 monoclonal antibody, which recognizes galactose-deficient IgA1, is typically positive in IgAN but may be weak or negative in IgA-type MGRS. Recent reports have described IgA-PGNMID and IgA-MIDD as rare manifestations of IgA-type MGRS, occasionally showing negative KM55 staining and restricted IgA subclass expression. We evaluated the diagnostic value of light chain and IgA subclass staining in IgA-dominant glomerular deposits.

We retrospectively reviewed cases diagnosed between January 2015 and August 2024 that demonstrated IgA-dominant glomerular deposition in native kidney biopsies. We analyzed κ/λ light chain restriction, IgA subclass predominance, KM55 intensity, pathological diagnosis, presence of serum M-protein, and renal outcomes, and assessed their association with the final clinical diagnosis.

Among 328 cases with IgA-dominant glomerular deposits, 302 were diagnosed as IgAN, 19 as IgA vasculitis, and 7 as other diseases. Light chain predominance (≥ 1+) was observed in 14 κ-dominant and 36 λ-dominant cases (15.3%), and ≥ 1.5+ in 10 κ and 16 λ cases (8.0%). The IgA2 subclass was comparable to IgA1 (difference −0.5 to +0.5) in 26 cases and only one case showed IgA2 predominance.
Among 48 cases with ≥ 1+ light chain predominance and subclass imbalance (14 κ, 34 λ), the pathological diagnoses were 45 IgAN, 1 IgA vasculitis, 1 IgA2-κ MIDD, and 1 suspected IgA1-λ PGNMID.
Of 23 cases with available follow-up (mean age 42.8 ± 14.6 years, mean eGFR 73.1 ± 27.6 mL/min/1.73 m², proteinuria 1.6 ± 2.0 g/gCr), all were negative for serum M-protein. Fifteen patients received steroid pulse therapy, and 13 achieved proteinuria < 1 g/gCr; one improved after an additional steroid pulse, and one was refractory to treatment and was diagnosed as IgA1-κ PGNMID on repeat biopsy, in which weak KM55 staining provided a diagnostic clue. The other patient with suspected IgA1-λ PGNMID responded to repeated steroid pulses plus cyclosporine, achieving partial remission (< 1 g/gCr).

Light chain restriction in IgA-dominant glomerular deposition is not uncommon but often reflects polyclonal IgA nephropathy rather than MGRS. While KM55 staining for galactose-deficient IgA1 is useful for differentiating IgAN from monoclonal IgA deposition, its negativity or weak reactivity should raise suspicion for IgA-type MGRS. Ultimately, IgA-type MGRS should be diagnosed through an integrated assessment of light chain restriction, IgA subclass predominance, KM55 staining pattern, and clinical course, supported by repeat biopsy and clone-directed evaluation when indicated.

Kewords